|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||470.603 g/mol|
|3D model (JSmol)|
|(what is this?)|
Bazedoxifene, or bazedoxifene acetate, is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. Bazedoxfiene is the result of an exclusive research collaboration between Wyeth Pharmaceuticals and Ligand Pharmaceuticals.
It is also being studied for possible treatment of breast cancer and pancreatic cancer.
As of December 2011, the FDA have not given approval for the use of bazedoxifene in the US.
On October 3, 2013 the FDA approved the combination product of bazedoxifene 20 mg with 0.45 mg Premarin (conjugated estrogens) for the treatment of menopausal osteoporosis and the treatment of moderate to severe hot flushes. This is the first approved hormone replacement therapy product that contains a SERM (bazedoxifene) and an estrogen.
- Biskobing, D. M. (2007). "Update on bazedoxifene: A novel selective estrogen receptor modulator". Clinical interventions in aging. 2 (3): 299–303. PMC . PMID 18044180.
- Gordon W. Gribble (9 October 2010). Heterocyclic Scaffolds II:: Reactions and Applications of Indoles. Springer Science & Business Media. pp. 14–. ISBN 978-3-642-15732-5.
- "Drugs@FDA - Drug Names Beginning with "B"". Food and Drug Administration. 7 July 2009. Archived from the original on 11 July 2009. Retrieved 2009-07-08.
- "EPARs for authorised medicinal products for human use - Conbriza". European Medicines Agency. 26 May 2009. Archived from the original on 11 June 2009. Retrieved 2009-07-08.